Global Heart Blocks Treatment Market Size study & Forecast, by Type of Heart Block (First-degree heart blocks, Second-degree heart blocks, Third-degree heart blocks), Mode Of Treatments (Transcutaneous pacing (TCP), Pacemaker, Medication, Anti-arrhythmic

Global Heart Blocks Treatment Market Size study & Forecast, by Type of Heart Block (First-degree heart blocks, Second-degree heart blocks, Third-degree heart blocks), Mode Of Treatments (Transcutaneous pacing (TCP), Pacemaker, Medication, Anti-arrhythmic drugs) and Regional Analysis, 2022-2029

Global Heart Blocks Treatment Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Heart Block is a condition in which heart beats irregularly and slower than usual. This irregular heartbeat is due to a delay, obstruction, along the pathway that electrical impulses travel through to make the heartbeat. Heart blocks are caused by an injury or damage to the heart muscle or valves. Moreover, heart block affect heart’s blood pumping capability, hence the muscles and organs, including the brain, do not get enough oxygen to function properly. The increasing prevalence of heart diseases and growing percentage of aging individuals are key factors driving the market growth.

Heart diseases are categorized as one of the leading causes of premature death globally. According to World Health Organization (WHO)’s estimates – an estimated 17.9 million people died from cardiovascular diseases (CVDs) in 2019, witnessing for approximately 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke . Additionally, around 38% premature deaths were caused by CVDs. Moreover, as per European Society of Cardiology – as of 2019, every year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union region. Also, growing healthcare infrastructure in developing regions and rising technological advancement in healthcare facilities would create lucrative growth prospectus for the market over the forecast period. However, the high cost of Heart Blocks Treatment stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Heart Blocks Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the presence of leading market players and increasing incidences of cardiovascular diseases in the region. Whereas Asia Pacific is expected to grow with a highest CAGR during the forecast period, owing to factors such as rising geriatric and target populations, and growing healthcare infrastructure in the region.

Major market player included in this report are:
Medtronic Plc
St. Jude Medical Inc.
SORIN S.p.A.
Boston Scientific Corporation
Biotronik SE & Co. KG
Abbott Laboratories
MicroPort Scientific Corporation
Koninklijke Philips N.V.
Boston Scientific Corporation
LivaNova PLC

Recent Developments in the Market:
 In September 2022, Bayer launched a novel heart failure drug in India that it has co-developed with Merck. The drug named Verquvo (vericiguat) is the first novel treatment approved to reduce the risk of deaths associated with cardiovascular deaths and repeated hospitalisation among heart failure patients.

Global Heart Blocks Treatment Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type of Heart Block, Mode of Treatment, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type Of Heart Block
First-degree heart blocks
Second-degree heart blocks
Third-degree heart blocks
By Mode Of Treatments
Transcutaneous pacing (TCP)
Pacemaker
Medication
Anti-arrhythmic drugs

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Medtronic Plc
St. Jude Medical Inc.
SORIN S.p.A.
Boston Scientific Corporation
Biotronik SE & Co. KG
Abbott Laboratories
MicroPort Scientific Corporation
Koninklijke Philips N.V.
Boston Scientific Corporation
LivaNova PLC

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.